S5 - E21.1 - The Updated MASLD CPG: Introductions
Send us a text Two of the co-authors of the upgraded MASLD Clinical Practice Guidelines, Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to discuss the guidelines. The theme for the conversation is "introductions". First, the audience is introduced to co-authors Elisabetta Bugianesi and Frank Tacke, neither of whom has Surfed the Tsunami before. Both Elisabetta and Frank have unusual answers to the "one thing our audience would not expect about you if yo...
29 Kesä 20249min
S5 - E21 - Reviewing The Updated ESL-EASD-EASO MASLD Clinical Practice Guidelines
Send us a text 00:00:00 - Surf's Up: Season 5 Episode 21 One important session at the EASL Congress 2024 involved the presentation of the new MASLD Clinical Practice Guidelines. CPG co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to share their perspectives on the guidelines' development some key recommendations. 00:09:36 - Revising the guidelines Roger asks the co-authors to describe the process that led to the 2021 decision to revise ...
27 Kesä 202452min
S5 - E20.6 - From the Vault: FGF-21s and "Twin-cretins" At EASL Congress 2023
Send us a text In this conversation from July 2023, Stephen Harrison, Jörn Schattenberg and Roger Green discuss the implications of presentations on the FGF-21 agent efruxifermin and the dual GLP/glucagon agonists pemvidutide and efinopegdutide. Here is the description Roger wrote for the original conversation: In this session, conversation shifts from resmetirom to Mazen Noureddin's "NASH Monopoly" game and focuses on the value of FGF-21s and glucagon agents. Stephen posits two commen...
23 Kesä 202414min
S5 - E20.5 - Drug Development Highlights From EASL Congress 2024: Denifenstat, SPECIAL and Other Stories
Send us a text Mazen Noureddin and Naim Alkhouri join Jörn Schattenberg and Roger Green to discuss some of the other major drug development stories from the EASL Congress 2024, with special focus on denifenstat, ION-224 and TAK-227, and to review the SPECIAL study on bariatric surgery and cirrhosis. The panelists concur that all three of these agents have potential value in therapy. Naim expresses some concern about how broad denifestat use will be based on its side effect profile. Lat...
23 Kesä 202413min
S5 - E20.4 - Drug Development Highlights From EASL Congress 2024: Are FGF-21s Induction Therapy or a "MASH Cure"?
Send us a text Mazen Noureddin and Naim Alkhouri join Jörn Schattenberg and Roger Green to focus on the role FGF-21s will play in long-term advanced fibrosis treatment: induction or long-term therapy...or might we even think of the class as being able to produce a "MASH cure?" Responding to Naim's comment closing the previous discussion, Mazen questions why we regard FGF-21 agents as induction therapies given that it appears to be as well tolerated as the oral agents and maintains such...
23 Kesä 202410min
S5 - E20.3 - Drug Development Highlights From EASL Congress 2024: "Twin-cretins" and efruxifermin
Send us a text Naim Alkhouri and Mazen Noureddin join Jörn Schattenberg and Roger Green to discuss issues regarding incretin agonists and results from the efruxiermin late-breaker at the EASL Congress 2024. Naim shares his general excitement about glucagon agents in general. He mentions that the efinopegdutide study included a semaglutide cell, which showed further reduction in liver fat vs. the GLP-1 agent. Jörn comments on the high level of tolerability in the survodutide trials. Mazen ...
22 Kesä 202414min
S5 - E20.2 - Drug Development Highlights From EASL Congress 2024: Tirzepatidate and other "Twin-cretins"
Send us a text Mazen Noureddin and Naim Alkhouri join Jörn Schattenberg and Roger Green to discuss the tirzepatide late-breaker at the EASL Congress 2024 and other "Twin-cretins," all of which are GLP-glucagon combinations. "Twin-cretins" is the name Jörn has coined for agents with a GLP-1 agonist plus another incretin effect. Tirzepatide is a GLP/GIP agent, while survodutide and the agents discussed last year, pemvidutide and efinopegdutide, are GLP/gluagons. Naim reviews the r...
22 Kesä 202411min
S5 - E20.1 - Drug Development Highlights From EASL Congress 2024: Resmetirom
Send us a text Naim Alkhouri and Mazen Noureddin join Jörn Schattenberg and Roger Green to discuss some of the new research on resmetirom at the EASL Congress 2024. Mazen begins this discussion by covering a paper he presented on Stephen's behalf, looking at dose-response with resmetirom. The analysis indicated that PDFF and histology improvements at the 100mg dose were greater than at the 80mg dose. Mazen speculates that the higher dose might provide a greater anti-fibrotic response as well...
22 Kesä 202410min
